Zaid E. Bustami

Zaid E. Bustami

Auto-generated profile, based on publicly available information

Zaid E. Bustami

Columbia University 2 New York, NY

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
In the phase 2 trial SWOG S1616 (NCT03033576), patients with advanced melanoma with primary resistance to anti-PD-1/L1 therapies had improved outcomes on the combination of the anti-CTLA-4 antibody ipilimumab with continued anti-PD-1 with nivolumab, over ipilimumab alone. Baseline biopsies from patients responsive to combination therapy had increased transcriptomic expression of complement by myeloid cells, interferon pathways by endothelial cells, and oxidative phosphorylation and lipid metabolism by melanoma cells. Using spatial proteomics, some on-therapy biopsies from patients responding to combination therapy had networks of activated CD8 T cells nearby melanoma cells, while others had T cells and myeloid cells, reflective of different timepoints in a dynamic antitumor response. Conversely, biopsies from patients progressing on combination immunotherapy displayed impaired T-cell infiltration adjacent to plasma cells. Our results define cellular neighborhoods and transcriptomes in melanoma biopsies when reversing resistance to anti-PD-1 with the addition of anti-CTLA4, and plasma cell sheets in non-responding biopsies.

1 September 2026
Verified
Other
Open access
PDF file
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
Supplementary Figure S7 shows the evaluation of TLS signatures in RNAseq and MIBI samples.

1 September 2026
Verified
Other
Open access
PDF file
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
Supplementary Figure S6 shows the TCR/BCR repertoire metrics in RNAseq data from biopsies from patients nonresponsive to combination therapy.

1 September 2026
Verified
Other
Open access
PDF file
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
Supplementary Figure S1 shows the processing and review of sample processing for WES, RNAseq, and MIBI.

1 September 2026
Verified
Other
Open access
PDF file
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
Supplementary Figure S2 shows the genomic variants detected by WES and statistical analaysis of WES data.

1 September 2026
Verified
Other
Open access
PDF file
KCKatie M. Campbell
Katie M. Campbell
DCDaniel Guorui Chen
Daniel Guorui Chen
ZBZaid E. Bustami
Zaid E. Bustami
NDNataly Naser Al Deen
Nataly Naser Al Deen
EMEgmidio Medina
Egmidio Medina
ARAntoni Ribas
Antoni Ribas
Supplementary Methods contains additional methods details with a data dictionary for the supplementary tables.